Cure My Disease

Don't miss your cure!

 Log in / Sign up

Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early

NCT ID NCT05015816

Diagnosis Sponsor: Oxford University Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests an AI tool called MoleGazer that uses total body photography to track moles over time, similar to how astrophysicists map the night sky. The goal is to automatically spot new or changing moles that could be early signs of melanoma. Researchers are recruiting people at high risk for melanoma to take three-monthly photos, as well as others who already get total body photography as standard care. If it works, this approach could make melanoma detection faster and more accurate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Total body photography with AI analysis
What this could lead to
If successful, this AI tool could help spot melanoma earlier by automatically detecting new or changing moles, potentially saving lives.
What could go wrong
This is an early feasibility study, so the algorithm may not yet be accurate enough for clinical use. It also requires high-quality images and regular follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

374 people

The number who actually took part.

Started

Sep 2021

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Male or Female, aged 18-80 years old In addition for Group A: 1. Willing to attend for additional study visits and total body photography imaging 2. High-risk melanoma patients including: * Dysplastic / atypical naevus syndrome (\> 60 moles +/- personal history of melanoma) * Family history of melanoma * Past history of at least two primary melanoma or melanoma-in situ * At least 3 first-degree or second-degree relatives with prior melanoma * CDKN2A or CDK4 germline mutation * Individuals with multiple naevi (\>25) who are immunosuppressed from any cause (e.g. organ transplant recipients, chronic lymphocytic leukaemia, etc.) In addition for Group B: ● Has previously had total body photography imaging OR will have total body photography as part of standard care Exclusion Criteria: The participant may not enter the study if ANY of the following apply: * Patient unable to consent * Patient with active malignancy affecting any organ and receiving any cancer-specific treatment * Poor mobility / unable to hold recommended positions for standard TBP imaging * Individuals who do not understand English In addition for Group A: ● Unable to attend for three-monthly study visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma (skin) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanocytic nevus melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma (skin) Moles multiple benign

Contacts and locations

Locations

  • Churchill Hospital

    Headington, Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.